Development trends for monoclonal antibody cancer therapeutics. (Q36790534)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Development trends for monoclonal antibody cancer therapeutics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Viia E Valge-Archer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

349-356

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

Monoclonal antibody successes in the clinic

29 December 2019

cites work

1 reference

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

Identification and validation of cell surface antigens for antibody targeting in oncology

31 March 2020

1 reference

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

31 March 2020

1 reference

Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies

31 March 2020

1 reference

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

31 March 2020

1 reference

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

31 March 2020

1 reference

Replacing the complementarity-determining regions in a human antibody with those from a mouse

31 March 2020

1 reference

Reshaping human antibodies for therapy

31 March 2020

1 reference

Human antibodies from transgenic animals

31 March 2020

1 reference

Phage antibodies: filamentous phage displaying antibody variable domains

31 March 2020

1 reference

Progress in immunoconjugate cancer therapeutics

31 March 2020

1 reference

Antibody targeted drugs as cancer therapeutics

31 March 2020

1 reference

Antibody-targeted radiation cancer therapy

31 March 2020

1 reference

Metabolic properties of IgG subclasses in man

31 March 2020

1 reference

Monoclonal antibody therapy of cancer

31 March 2020

1 reference

Overview of monoclonal antibodies in cancer therapy: present and promise

31 March 2020

1 reference

Monoclonal antibodies as therapeutics in oncology

31 March 2020

1 reference

Complement function in mAb-mediated cancer immunotherapy

31 March 2020

1 reference

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

31 March 2020

1 reference

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

31 March 2020

1 reference

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

31 March 2020

1 reference

Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

31 March 2020

1 reference

Monoclonal antibodies as therapeutic agents for cancer

31 March 2020

1 reference

Herceptin: mechanisms of action and resistance

31 March 2020

1 reference

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

31 March 2020

1 reference

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

31 March 2020

1 reference

Immunostimulatory monoclonal antibodies for cancer therapy

31 March 2020

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

31 March 2020

1 reference

Upping the ante on antibodies.

31 March 2020

1 reference

Selecting and screening recombinant antibody libraries

31 March 2020

1 reference

Potent antibody therapeutics by design

31 March 2020

1 reference

Strategies for optimizing combinations of molecularly targeted anticancer agents

31 March 2020

1 reference

Multitargeted therapy: can promiscuity be praised in an era of political correctness?

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2241

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431406%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference